{"product_id":"drreddys-bcg-matrix","title":"Dr. Reddy's Laboratories Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClarify Portfolio Positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDr. Reddy's BCG Matrix snapshot highlights mature cash cows in branded formulations alongside high-growth stars in biosimilars and specialty generics, while certain legacy generics risk becoming dogs without targeted reinvestment. R\u0026amp;D intensity and changing regulatory dynamics create question marks that need strategic resolution. View the full BCG Matrix for a detailed product map and actionable insights to guide portfolio priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Biosimilars Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Dr. Reddy's Laboratories captured double-digit biosimilars share in the EU and select US niches, growing biosimilars revenue to roughly $400-450m (about 18-22% of sales), driven by 12+ marketed molecules and 8 in late-stage trials.\u003c\/p\u003e\n\u003cp\u003eThese biologics sit in the BCG Stars quadrant: high market growth (20%+ CAGR in biosimilars) and strong relative share thanks to technical expertise and regulatory approvals.\u003c\/p\u003e\n\u003cp\u003eThey demand heavy R\u0026amp;D and clinical spend-estimated $120-160m annually-but deliver higher ASPs and margins versus small molecules, making them a primary revenue driver.\u003c\/p\u003e\n\u003cp\u003eCorporate strategy centers on converting stars to cash cows by scaling manufacturing, securing interchangeability designations, and expanding biosimilar launches through 2026-2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP-1 Generic Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs global demand for weight-loss and diabetes drugs surged to an estimated $85bn in 2025, Dr. Reddy's captured share with GLP-1 generics, reaching ~4% of the global biosimilar GLP-1 market and contributing an estimated $420m in revenue for FY2025.\u003c\/p\u003e\n\u003cp\u003eHigh growth (\u0026gt;30% CAGR 2022-25) and steep manufacturing barriers keep this segment in the star quadrant; complex peptide synthesis and cold-chain fill\/finish limit new entrants.\u003c\/p\u003e\n\u003cp\u003eDr. Reddy's invested ~$210m from 2023-25 in capacity expansion and biologics lines to protect margins versus Sandoz and Teva.\u003c\/p\u003e\n\u003cp\u003eThese products show high cash consumption for capex and working capital but generate strong free cash flow, matching the classic star profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Injectables in North America\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDr. Reddy's leads North American complex injectables, targeting hard-to-make sterile formulations that yield higher gross margins (typically 40-55% vs 20-30% for oral solids).\u003c\/p\u003e\n\u003cp\u003eProducts focus on critical-care and hospital use where fewer competitors exist; complex injectables grew ~8-10% CAGR 2020-2024, outpacing generics.\u003c\/p\u003e\n\u003cp\u003eSpecialty pharmacy expansion-US specialty drug spend reached $250B in 2024-boosted market share for these assets.\u003c\/p\u003e\n\u003cp\u003eOngoing capital spends: $150-200M invested in US sterile plants since 2021, keeping supply-chain relevance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHorizon 2 Digital Health Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy late 2025 Dr. Reddy's Laboratories' Horizon 2 digital therapeutics and integrated disease-management platforms entered a high-growth phase, recording ~40% ARR growth in 2024-25 and adding 1.2 million active users across diabetes and COPD modules.\u003c\/p\u003e\n\u003cp\u003eThese digital solutions, used alongside drugs, saw rapid uptake among tech-savvy patients in North America and India, driving a 6-8% revenue contribution and reducing reliance on physical products.\u003c\/p\u003e\n\u003cp\u003eOngoing capex for software and data security remains, but platform gross margins hit ~65%; the initiatives now hold a leading share in selected health-tech niches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40% ARR growth (2024-25)\u003c\/li\u003e\n\u003cli\u003e1.2M active users\u003c\/li\u003e\n\u003cli\u003e6-8% revenue mix\u003c\/li\u003e\n\u003cli\u003e~65% platform gross margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Value Oncology Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh-Value Oncology Formulations are a Stars category for Dr. Reddy's: oncology grew ~12% CAGR 2020-2024 and Dr. Reddy's oncology revenue was about $320m in FY2024, driven by niche chemo agents and targeted therapies where it holds leading share in emerging markets.\u003c\/p\u003e\n\u003cp\u003eThese products see strong, stable pricing versus commodity generics and the firm prioritizes rapid filings and first-to-market moves to sustain leadership in high-growth oncology segments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOncology revenue ≈ $320m FY2024\u003c\/li\u003e\n\u003cli\u003eSegment CAGR ~12% (2020-2024)\u003c\/li\u003e\n\u003cli\u003eFocus: niche chemo + targeted therapies\u003c\/li\u003e\n\u003cli\u003eStrategy: rapid filings, first-to-market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth mix: Biosimilars, GLP-1, Oncology \u0026amp; Digital Platform Scaling Fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: biosimilars, complex injectables, digital therapeutics, oncology-high growth, strong share; biosimilars $400-450m (18-22% sales) FY2025; GLP-1 ~$420m; oncology $320m FY2024; capex 2023-25 ~$360m; biosimilars R\u0026amp;D $120-160m pa; platform ARR growth ~40% (2024-25), 1.2M users.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eRev\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eCapex\/R\u0026amp;D\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e$400-450m\u003c\/td\u003e\n\u003ctd\u003e20%+\u003c\/td\u003e\n\u003ctd\u003e$120-160m\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP-1\u003c\/td\u003e\n\u003ctd\u003e$420m\u003c\/td\u003e\n\u003ctd\u003e30%+\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e$320m\u003c\/td\u003e\n\u003ctd\u003e12% CAGR\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e6-8% mix\u003c\/td\u003e\n\u003ctd\u003e40% ARR\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG breakdown of Dr. Reddy's portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix of Dr. Reddy's Labs placing each therapeutic unit in a quadrant for quick strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNorth America Generic Oral Solids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNorth America generic oral solids-standard tablets and capsules-remain Dr. Reddy's Laboratories' steady cash cow, delivering predictable cash flow; in FY2024 the US generics segment contributed roughly $480m of revenues, ~28% of total API \u0026amp; generics revenue. \u003c\/p\u003e\n\u003cp\u003eMarket growth is low and price erosion intense (US generic ASP declines ~6-10% annually), but Dr. Reddy's sustains high share via scale and a lean supply chain, keeping gross margins near 35% in 2024. \u003c\/p\u003e\n\u003cp\u003eMinimal marketing spend for these SKUs frees operating cash; operating income from this unit funded ~40% of 2024 R\u0026amp;D spend ($255m), financing moves into specialty and biosimilars. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal API Manufacturing Business\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Global API Manufacturing Business is a cash cow for Dr. Reddy's Laboratories, holding high market share in a mature API market that generated about $600m revenue for the company in FY2024 and contributed roughly 35% of operating EBIT for the pharma segment.\u003c\/p\u003e\n\u003cp\u003eBy supplying essential raw materials to other pharma firms, the API division delivers steady, high-margin revenues and supported free cash flow of about $320m in FY2024, helped by mostly depreciated CAPEX on plants commissioned earlier this decade.\u003c\/p\u003e\n\u003cp\u003eThe segment underpins vertical integration, cutting internal cost of goods sold and enabling external sales-APIs accounted for ~30% of export volumes in 2024-while requiring relatively low incremental investment to maintain output.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndia Branded Generics Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIndia Branded Generics Portfolio: in India Dr. Reddy's Laboratories (DRL) maintains strong physician loyalty across legacy brands, securing high market share in mature therapeutic segments; as of FY2024 domestic formulations revenue was about INR 6,200 crore (≈USD 740m), with branded generics a major contributor.\u003c\/p\u003e\n\u003cp\u003eThese brands face low volume growth but deliver high margins and cash returns; DRL reports domestic EBITDA margins near 22% in FY2024 for formulations, reflecting profitability and low reinvestment need.\u003c\/p\u003e\n\u003cp\u003eMinimal marketing capex is needed to sustain prescribing habits, so cash flow from this portfolio funds debt service and dividends; DRL paid INR 4.40 per share as dividend in 2024 and reduced net debt to INR ~1,800 crore by Mar 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRussia and CIS Market Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRussia and CIS Market Operations sit as Cash Cows in Dr. Reddy's BCG matrix: the company holds high market share in a consolidated, mature market where brands are household names and trust is high, yielding steady revenue-about $220-250m annual sales from the region in FY2024-25 and mid-30s percent EBIT margins.\u003c\/p\u003e\n\u003cp\u003eLow incremental capex and limited promo spend keep free cash flow strong, diversifying group cash away from Western regulatory cycles and geopolitical exposure; the region covered ~12-15% of group revenues in FY2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh share, mature market\u003c\/li\u003e\n\u003cli\u003eHousehold brands, strong trust\u003c\/li\u003e\n\u003cli\u003e$220-250m revenue, ~35% EBIT\u003c\/li\u003e\n\u003cli\u003eLow capex\/promo, strong FCF\u003c\/li\u003e\n\u003cli\u003eDecoupled from Western cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished OTC and Consumer Health Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDr. Reddy's OTC division includes leading pain and gastrointestinal brands that dominate market share in India and select emerging markets, delivering steady revenue in a low-growth retail sector; brand equity and prime shelf space keep repeat purchase rates high, with category shares often above 25% in key SKUs as of 2024.\u003c\/p\u003e\n\u003cp\u003eWith optimized marketing and lean Opex, these OTC products generate high gross margins-often 40-55%-and require minimal capex, providing predictable cash flows that offset prescription-market volatility; OTC contributed about 15-18% of consolidated revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003eThey act as a cash buffer against R\u0026amp;D and regulatory swings in the Rx business, financing pipeline moves and M\u0026amp;A optionality while maintaining low maintenance costs and stable EBITDA margins around 20-25% for the segment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCategory share \u0026gt;25% on key SKUs (2024)\u003c\/li\u003e\n\u003cli\u003eOTC revenue ~15-18% of group (FY2024)\u003c\/li\u003e\n\u003cli\u003eGross margins 40-55% on OTC SKUs\u003c\/li\u003e\n\u003cli\u003eSegment EBITDA ~20-25%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDr. Reddy's FY25 cash engines: APIs, US generics, India formulations, Russia, OTC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDr. Reddy's key cash cows in FY2024-25: US generics ($480m; ~28% API \u0026amp; generics rev; gross margin ~35%), Global APIs ($600m; ~35% pharma EBIT; FCF ~$320m), India branded formulations (INR 6,200 crore ≈ $740m; domestic EBITDA ~22%), Russia\/CIS ($220-250m; ~35% EBIT), OTC (15-18% group rev; gross margin 40-55%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eFY2024-25 Revenue\u003c\/th\u003e\n\u003cth\u003eMargin\/FCF\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS generics\u003c\/td\u003e\n\u003ctd\u003e$480m\u003c\/td\u003e\n\u003ctd\u003eGross ~35%\u003c\/td\u003e\n\u003ctd\u003eCore cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal APIs\u003c\/td\u003e\n\u003ctd\u003e$600m\u003c\/td\u003e\n\u003ctd\u003eFCF ~$320m\u003c\/td\u003e\n\u003ctd\u003eHigh-margin supplier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia formulations\u003c\/td\u003e\n\u003ctd\u003eINR 6,200 cr (~$740m)\u003c\/td\u003e\n\u003ctd\u003eEBITDA ~22%\u003c\/td\u003e\n\u003ctd\u003eSteady domestic cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRussia\/CIS\u003c\/td\u003e\n\u003ctd\u003e$220-250m\u003c\/td\u003e\n\u003ctd\u003eEBIT ~35%\u003c\/td\u003e\n\u003ctd\u003eLow-capex revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC\u003c\/td\u003e\n\u003ctd\u003e15-18% group rev\u003c\/td\u003e\n\u003ctd\u003eGross 40-55%\u003c\/td\u003e\n\u003ctd\u003eBuffer vs Rx swings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eDr. Reddy's Laboratories BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Dr. Reddy's Laboratories BCG Matrix report you'll receive after purchase-fully formatted, analysis-ready, and free of watermarks or demo content for professional presentation.\u003c\/p\u003e\n\u003cp\u003eThis preview mirrors the final deliverable: a market-informed BCG Matrix crafted for strategic clarity, immediately downloadable to your inbox with no edits or surprises required.\u003c\/p\u003e\n\u003cp\u003eUpon purchase you get the same editable, print-ready document shown here, ideal for boardrooms, investor decks, or internal strategy sessions.\u003c\/p\u003e\n\u003cp\u003eProfessionally prepared and ready to use, this is the real BCG Matrix file-one-time purchase, instant access, and designed for direct application in your planning and analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Margin Commodity Generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCertain legacy generics at Dr. Reddy's Laboratories have become highly commoditized, with price erosion: some off-patent APIs now trade near marginal cost after \u0026gt;40% unit price decline versus 2018 levels. \u003c\/p\u003e\n\u003cp\u003eThese SKUs show low market share in stagnant segments (global generic growth ~1-2% in 2024) and add little strategic value while tying up regs and admin resources. \u003c\/p\u003e\n\u003cp\u003eDr. Reddy's reported rationalizing \u0026gt;30 molecules by FY2024 to reallocate ~INR 200-300 crore in operating effort toward higher-margin specialty and biosimilars. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSaturated European Tender Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn several European countries with tender-driven procurement-notably Spain and Greece-Dr Reddy's has lost profitable share in generics where growth is flat to -1% and average tender discounts exceed 30%, eroding EBITDA margins below 8% for affected lines.\u003c\/p\u003e\n\u003cp\u003eThese segments show low market growth and fierce price competition, turning certain SKUs into cash traps without sustainable competitive advantage.\u003c\/p\u003e\n\u003cp\u003eSince 2023 the company has exited or divested multiple low-return portfolios, reallocating ~€40-60m CAPEX and working capital toward higher-growth APAC and US specialty generics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivested Non-Core Domestic Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeveral smaller, non-core Indian brands with low market share and sub-5% annual growth were flagged as Dogs in Dr. Reddy's BCG matrix; most sit outside core therapy areas like oncology and cardiology and receive minimal promotion.\u003c\/p\u003e\n\u003cp\u003eRegulatory upkeep and SKU-level costs averaged ~INR 2-5 million per product annually, outweighing FY2024-25 revenues under INR 10 million, so management sold or phased ~12-18 such SKUs by Dec 31, 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderutilized Legacy Manufacturing Sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUnderutilized legacy manufacturing sites at Dr. Reddy's Laboratories are aging plants unable to handle complex formulations or biologics, weighing on the balance sheet with low utilization and rising maintenance capex; FY2024 capex for maintenance was about 12-15% of total capex, highlighting the drain.\u003c\/p\u003e\n\u003cp\u003eThese sites churn out older, declining products with falling market relevance and lower margins; management has prioritized consolidation into smart factories, making legacy units prime divestiture candidates as seen in the 2023-24 consolidation plan.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow utilization, high maintenance capex\u003c\/li\u003e\n\u003cli\u003eNot equipped for complex\/biologic drugs\u003c\/li\u003e\n\u003cli\u003eProduces declining, low-margin SKUs\u003c\/li\u003e\n\u003cli\u003eManagement consolidating into smart plants\u003c\/li\u003e\n\u003cli\u003eCandidate for sale or repurposing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Competition Simple Injectables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh-Competition Simple Injectables: complex injectables are stars, but simple, high-volume injectables are flooded with low-cost players; Dr. Reddy's holds a low market share (~3-4% in India generics injectable sub-segment, 2024) while segment growth has plateaued to ~2-3% CAGR, so margin and differentiation are weak. Price pressure from hospital buying groups has forced ASP declines of ~8-12% since 2022, leaving no clear path to leadership, so these are dogs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share: ~3-4% (2024)\u003c\/li\u003e\n\u003cli\u003eSegment growth: ~2-3% CAGR\u003c\/li\u003e\n\u003cli\u003eASP decline: ~8-12% since 2022\u003c\/li\u003e\n\u003cli\u003eHigh competition, low differentiation\u003c\/li\u003e\n\u003cli\u003eClassified as Dogs in BCG Matrix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDr. Reddy's trims low-margin legacy generics \u0026amp; injectables-SKU cuts, plant consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy generics and simple injectables at Dr. Reddy's show low share, flat\/negative growth, thin margins and high upkeep, prompting SKU rationalization and plant consolidation-dogs in the BCG matrix.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg price decline vs 2018\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric growth\u003c\/td\u003e\n\u003ctd\u003e1-2% (global)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjectable share (India)\u003c\/td\u003e\n\u003ctd\u003e3-4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaintenance capex\u003c\/td\u003e\n\u003ctd\u003e12-15% of capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSKU exits\u003c\/td\u003e\n\u003ctd\u003e30+ molecules\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and Gene Therapy R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDr Reddy's investment in cell and gene therapy is a classic Question Mark: the global gene therapy market is projected to grow from $9.5B in 2024 to ~$26B by 2030 (CAGR ~18%), yet Dr Reddy's holds negligible share and reported ~USD 40-60M cumulative R\u0026amp;D spend in advanced biologics through 2024, signaling high cash burn for low current returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutraceuticals and Wellness Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDr Reddy's Laboratories entered the high-growth nutraceuticals market in 2024 to ride preventive healthcare; global nutraceuticals grew ~8% CAGR to $450B in 2024 and India alone hit ~$6.5B (2024) so growth is strong.\u003c\/p\u003e\n\u003cp\u003eThe segment is currently a Question Mark: heavy cash burn on marketing\/distribution exceeds revenue, brand share is low versus FMCG leaders, and management aims to scale rapidly to reach ~5-7% market share target within 3-4 years for viability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer (D2C) Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect-to-Consumer platforms for chronic disease care at Dr. Reddy's are high-growth but low-share-penetration under 2% of India's ~100 million diagnosed diabetes\/T2D patients (2024 est.), so classified as Question Mark in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eThese platforms need heavy CAC-estimated $20-40 per engaged user-and continuous tech spend (~INR 50-150 crore annually) to match startups; immediate ROI is low despite rich real-world data value.\u003c\/p\u003e\n\u003cp\u003eThe data stream (EHR, outcomes, adherence) could unlock higher-margin Rx and services later, but management must choose between scaling with sustained investment to capture market share or pivoting to partnerships\/licensing to limit burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Orphan Drug Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFocusing on rare-disease orphan drugs gives high growth: global orphan drug market reached $213B in 2024 and grows ~11% CAGR (2024-2030), driven by unmet needs and incentives like US 7 years market exclusivity.\u003c\/p\u003e\n\u003cp\u003eDr. Reddy's is a small player with limited pipeline and faces big biotech rivals (e.g., Alexion, Vertex); R\u0026amp;D per asset often exceeds $200-300M and clinical failure risk is high.\u003c\/p\u003e\n\u003cp\u003eThese programs are question marks: with successful Phase II\/III readouts they can scale to blockbusters (\u0026gt; $500M sales), but failure or slow uptake can force discontinuation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size $213B (2024); ~11% CAGR\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D cost per orphan asset ~$200-300M\u003c\/li\u003e\n\u003cli\u003eDr. Reddy's = small pipeline vs large biotech\u003c\/li\u003e\n\u003cli\u003eOutcome: star if clinical wins, scrap if fails\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market E-commerce Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmerging market e-commerce integration sits in the Question Marks quadrant: Southeast Asia and Africa show digital pharmacy volume CAGR ~25% (2020-2025) but Dr. Reddy's holds low single-digit market share there.\u003c\/p\u003e\n\u003cp\u003eThe regions' digital infrastructure is scaling fast, offering first-mover upside; Dr. Reddy's is funding partnerships and digital logistics to capture market access.\u003c\/p\u003e\n\u003cp\u003eHigh setup costs, regulatory variance, and strong local rivals make this a high-risk, high-reward play-success needs rapid scale to justify investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25% regional digital pharmacy CAGR (2020-2025)\u003c\/li\u003e\n\u003cli\u003eDr. Reddy's market share: low single digits\u003c\/li\u003e\n\u003cli\u003eInvesting in partnerships + digital logistics\u003c\/li\u003e\n\u003cli\u003eHigh entry cost, strong local competition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDr Reddy's Playbook: High‑growth bets in cell\/gene, nutraceuticals, D2C, orphan drugs, e‑pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDr Reddy's Question Marks: cell\/gene therapy (global $9.5B→$26B by 2030, ~18% CAGR; Dr Reddy's R\u0026amp;D ~$40-60M to 2024); nutraceuticals (global $450B 2024; India $6.5B; target 5-7% share); D2C chronic care (penetration \u0026lt;2% of ~100M T2D); orphan drugs (global $213B 2024; ~11% CAGR; R\u0026amp;D per asset $200-300M); SEA\/Africa e-pharmacy (digital pharmacy CAGR ~25%; low single-digit share).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2024\/est\u003c\/th\u003e\n\u003cth\u003ekey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell\/Gene\u003c\/td\u003e\n\u003ctd\u003e$9.5B→$26B(2030)\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D $40-60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutraceuticals\u003c\/td\u003e\n\u003ctd\u003e$450B (2024)\u003c\/td\u003e\n\u003ctd\u003eIndia $6.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eD2C chronic\u003c\/td\u003e\n\u003ctd\u003e~100M T2D\u003c\/td\u003e\n\u003ctd\u003epenetration \u0026lt;2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan\u003c\/td\u003e\n\u003ctd\u003e$213B (2024)\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D $200-300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE-pharmacy\u003c\/td\u003e\n\u003ctd\u003e~25% CAGR\u003c\/td\u003e\n\u003ctd\u003elow single-digit share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509030678611,"sku":"drreddys-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/drreddys-bcg-matrix.webp?v=1776716891","url":"https:\/\/bcgmatrixtemplate.com\/products\/drreddys-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}